ILiAD Biotechnologies BPZE1 Pertussis Vaccine Reaches Key Milestones Including Positive Phase 1b Clinical Study Data NEW YORK, July 05, 2017 (GLOBE NEWSWIRE) -- ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotechnology company, today announced promising results from its Phase 1b pertussis vaccine clinical...

Phase 1b Clinical Trial of BPZE1 Pertussis Vaccine Completes Enrollment of Randomized Study Groups NEW YORK, Feb. 19, 2016 (GLOBE NEWSWIRE) -- ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotechnology company, announced today that enrollment has been completed for three randomized groups...